Schrödinger, Llc Appoints Drug Discovery Veteran Nancy Thornberry to Board of Directors
September 24, 2019 at 07:00 am EDT
Share
Schrödinger, LLC announced the appointment of Nancy Thornberry, a biotech executive recognized for her extensive track record in drug discovery and development, to its Board of Directors. Ms. Thornberry, the Chief Executive Officer of Kallyope Inc., brings over 30 years of biopharma leadership to the board. Ms. Thornberry has received several awards for her scientific contributions, including the Merck Presidential Fellowship and Merck Directors Award, the Heroes of Chemistry Award from the American Chemical Society (ACS), the 2011 Thomas Alva Edison Patent Award from the Research and Development Council of New Jersey, and the 2011 Pharmaceuticals Research and Manufacturers of America (PhRMA) Discoverers Award.
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.